Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts
Signal Transduction and Targeted Therapy · 29.07.2024 · 9 (1)
DOI: 10.1038/s41392-024-01893-2 ↗Kurz gefasst
Leserbrief in der Zeitschrift Signal Transduction and Targeted Therapy, online erschienen am 29.07.2024. Verfasst von Marina Kolesnichenko und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany. marina.kolesnichenko@charite.de. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Synthetic Lethal Mutations. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research), Deutsche Forschungsgemeinschaft (German Research Foundation), Fritz Thyssen Stiftung (Fritz Thyssen Foundation).
Abstract (Originalsprache)
In a landmark study recently published in Nature , Petropoulous et al. demonstrated that synthetic lethality of poly(ADP-ribose) polymerase (PARP) inhibitors in cells with defective homologous recombination repair (HR) results predominantly from transcription replication conflicts (TRC) and not, as previously proposed, from PARP trapping on DNA 1 (Fig. 1 ). The article unveils a new mechanism behind synthetic lethality of PARP inhibitors with relevance for cancer therapy. Fig. 1 New mechanism for synthetic lethality mediated by PARP inhibitors. TRCs are a major cause of genome instability and DNA double-strand breaks (DSBs). Conflicts occur when DNA replication forks and elongating RNA polymerases collide and require PARP1, TIMELESS (TIM) and TIPIN (TIP) for resolution. PARP and TIM interact and signal TCR to the replisome. After binding to DNA lesions, PARP1 is activated and forms poly(ADP)-ribose (PAR) attached to itself and to other proteins. PARP1 inhibition or loss of PARP1, TIM or TIP results in the generation of DSBs which, in the absence of homologous repair capacity, result in cell death Full size image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany. marina.kolesnichenko@charite.de.
- Laboratory for Signal Transduction in Tumor Cells, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. scheidereit@mdc-berlin.de.
Förderung
- Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)
- Deutsche Forschungsgemeinschaft (German Research Foundation)
- Fritz Thyssen Stiftung (Fritz Thyssen Foundation)
Zitieren
APA
Kolesnichenko, M., & Scheidereit, C. (2024). Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01893-2
Vancouver
Kolesnichenko M, Scheidereit C. Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts. Signal Transduction and Targeted Therapy. 2024;9(1). doi:10.1038/s41392-024-01893-2
BibTeX
@article{Kolesnichenko2024,
author = {Kolesnichenko, Marina and Scheidereit, Claus},
title = {Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts},
journal = {Signal Transduction and Targeted Therapy},
year = {2024},
volume = {9},
number = {1},
doi = {10.1038/s41392-024-01893-2}
}
EUVIMED